The stock of Allarity Therapeutics Inc (NASDAQ: ALLR) has decreased by -13.99 when compared to last closing price of 0.95.Despite this, the company has seen a loss of -16.15% in its stock price over the last five trading days. globenewswire.com reported 2025-02-24 that Boston (February 24, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced that the new protocol for its Phase 2 clinical trial of stenoparib in ovarian cancer is set to begin and will be expected to provide critical data by end of summer 2026 for a pivotal registration trial.
Is It Worth Investing in Allarity Therapeutics Inc (NASDAQ: ALLR) Right Now?
Company’s 36-month beta value is 0.23.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ALLR is 3.39M, and currently, short sellers hold a 14.43% ratio of that floaft. The average trading volume of ALLR on February 25, 2025 was 1.88M shares.
ALLR’s Market Performance
The stock of Allarity Therapeutics Inc (ALLR) has seen a -16.15% decrease in the past week, with a -37.87% drop in the past month, and a -34.39% fall in the past quarter. The volatility ratio for the week is 10.13%, and the volatility levels for the past 30 days are at 14.60% for ALLR. The simple moving average for the last 20 days is -24.59% for ALLR’s stock, with a simple moving average of -84.07% for the last 200 days.
ALLR Trading at -23.53% from the 50-Day Moving Average
After a stumble in the market that brought ALLR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.69% of loss for the given period.
Volatility was left at 14.60%, however, over the last 30 days, the volatility rate increased by 10.13%, as shares sank -39.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.76% lower at present.
During the last 5 trading sessions, ALLR fell by -16.15%, which changed the moving average for the period of 200-days by -96.97% in comparison to the 20-day moving average, which settled at $1.0873. In addition, Allarity Therapeutics Inc saw -29.91% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ALLR
Current profitability levels for the company are sitting at:
- -221.46 for the present operating margin
- 0.89 for the gross margin
The net margin for Allarity Therapeutics Inc stands at -172.73. The total capital return value is set at -1.91. Equity return is now at value -391.95, with -109.68 for asset returns.
Based on Allarity Therapeutics Inc (ALLR), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -11.83. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -30.7.
Currently, EBITDA for the company is -12.08 million with net debt to EBITDA at 0.92. When we switch over and look at the enterprise to sales, we see a ratio of -120.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.75.
Conclusion
In a nutshell, Allarity Therapeutics Inc (ALLR) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
